Medical technology startup REEV has completed a $9.2 million funding round. The significant funding comes at a time when there is increasing confidence in the mission to develop intelligent, lightweight wearable robotics that can enhance the quality of life for patients facing movement challenges.

The latest funding round was led by leading investors Newfund Heka, Polytechnique Ventures, and Irdi Capital. Techstars, French soccer player Raphaël Varane, orthopedic surgeon Dr. Hervé Silbert, and a business angels group formed by Scala Patrimoine, a multi-family office, also participated in the funding round. The varied set of investors reflects the scope and potential influence of REEV’s mobility assistance innovation.

REES established in 2021 aims to change mobility assistance with the development of intelligent, lightweight wearable robotics. It is founded with the idea of enhancing quality life for individuals having trouble walking. It equips them to achieve independence and freedom in walking once again. 

Its dynamic team comprises 30 professionals, with bases in Boston, Massachusetts, and Toulouse, France. Thus, REEV stands as the spearhead in medical technology innovation.

REEV was co-founded by its CEO Amaury Ciurana and CTO Dr. Robin Temporelli. Amaury Ciurana graduated from ISAE-SUPAERO, a very successful engineer, with a €1 million Lopez-Loreta Award, and his entrepreneurial skills he improved in X-HEC Entrepreneurs and Learn2Launch at UC Berkeley. 

Dr. Robin Temporelli, Chief Technology Officer, has a Ph.D. in Mechatronics from the University of Sherbrooke and graduated with a Mechatronics Engineering degree from INSA Toulouse. Dr. Temporelli has been working in industry for more than 12 years, having also spent time at Airbus, where he has supported three patents and seven publications, showing his proficiency in the subject. 

Read also: BOW Robotics raises £4M to universal robotics software

Reev Innovative Solutions

REEV’s technology portfolio comprises two groundbreaking solutions designed to address the needs of patients with movement disorders:

REEV SENSE: This motion sensor system attaches to a patient’s shoe or leg, providing precise gait analysis. By delivering detailed insights into a patient’s walking patterns, REEV SENSE enables healthcare professionals to tailor interventions more effectively, facilitating improved rehabilitation outcomes.

DREEVEN: This is a wearable robotics system with electro-hydraulic technology for personalized knee support. DREEVEN is engineered to support patients with gait disorders, helping them walk freely and independently. The intelligent design of the system allows for adaptive assistance, providing support tailored to the needs of each user.

Read also: Swave Photonics Secures $28.3 Million to Revolutionize 3D Holographic Displays

Addressing Industry Challenges

Current exoskeleton technologies have been characterized by high weight, high costs, and poor personalization options. REEV addresses these limitations by developing lightweight and cost-effective solutions that can be highly personalized to the individual patient’s needs. In doing so, REEV hopes to make advanced mobility assistance more accessible to a wider patient population.

The newly obtained funds will help REEV make further progress on its development work. The company will complete the design of DREEVEN and conduct a clinical study at Boston University’s Sargent College of Health and Rehabilitation Sciences’ Neuromotor Recovery Lab, headed by Dr. Lou Awad. These moves are in line with the efforts to prepare for FDA trials with the goal of bringing REEV’s innovative solutions to the U.S. market.

The first collection of DREEVEN is going to be launched in 2026. That is a new step for REEV in changing the face of mobility assistance for patients with gait disorders. By applying leading-edge technology and a patient-centered approach, REEV is about to leave its mark on medical mobility solutions forever.